Session (CTI)

ISSUE: Medicines can bring value to patients, caregivers and society by, for example, keeping people in the workforce and advancing medical research and development. However, adopting broader value elements requires willingness and ability by all stakeholders and raises methods, evidence, and incentive challenges. Patients and society can benefit from innovations that improve health and produce spillover non-health effects. Researchers are developing new methods for measuring these elements, but technical and ethical challenges remain. Payers and health technology assessment (HTA) agencies consider criteria beyond cost-effectiveness in their deliberations, but guidance is limited and adoption is inconsistent, as HTA is typically tasked with informing reimbursement by the health system, leaving no clear answer to who should pay for non-health benefits. At the same time, the omission of broader value elements may miss opportunities to reward innovations that produce significant societal benefits. OVERVIEW: The session will address challenges in incorporating novel value elements into routine assessments and payer decisions. It will emphasise the need for stakeholder alignment on methodology, timing, evidence types, and incentives. The moderator will introduce the topic. Panellist 1 will present the patient perspective and discuss the areas of value that matter most to patients and how they can inform evidence generation at an early stage. Panellist 2 will discuss methodological challenges and research progress. Panellist 3 will cover payer challenges, including budgets restricted to the healthcare sector and uncertainty around broader value elements, as well as potential solutions. The discussion leader will engage the audience with polls and conclude with a panel discussion on developing systems to support the evidence generation, assessment, and utilisation of broader value elements.